Paclitaxel Encapsulated in Cationic Liposomes Diminishes Tumor Angiogenesis and Melanoma Growth in a “Humanized” SCID Mouse Model
- 1 March 2003
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 120 (3) , 476-482
- https://doi.org/10.1046/j.1523-1747.2003.12057.x
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Drugs that target angiogenesisNature Reviews Drug Discovery, 2002
- Metronomic scheduling: the future of chemotherapy?The Lancet Oncology, 2001
- Successful Treatment of Primary and Disseminated Human Lung Cancers by Systemic Delivery of Tumor Suppressor Genes Using an Improved Liposome VectorMolecular Therapy, 2001
- Hypoxia promotes fibrogenesis in human renal fibroblastsKidney International, 2000
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicityJournal of Clinical Investigation, 2000
- Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice.Journal of Clinical Investigation, 1998
- HECA-452+ T Cells Migrate Through Superficial Vascular Plexus but Not Through Deep Vascular Plexus EndotheliumJournal of Investigative Dermatology, 1997
- Factors influencing the efficiency of cationic liposome-mediated intravenous gene deliveryNature Biotechnology, 1997
- Human Delayed-Type Hypersensitivity Reaction in a SCID Mouse Engrafted with Human T Cells and Autologous SkinJournal of Investigative Dermatology, 1996
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971